Clinical and mycological predictors of cryptococcosis-associated immune reconstitution inflammatory syndrome

HIV-infected patients with treated cryptococcal meningitis are at risk for further neurological deterioration after commencing combination antiretroviral therapy (cART), mostly because of cryptococcosis-associated immune reconstitution inflammatory syndrome (C-IRIS). Identifying predictors of C-IRIS...

Full description

Saved in:
Bibliographic Details
Published inAIDS (London) Vol. 27; no. 13; pp. 2089 - 2099
Main Authors CHANG, Christina C, DORASAMY, Afton A, LEWIN, Sharon R, FRENCH, Martyn A, GOSNELL, Bernadett I, ELLIOTT, Julian H, SPELMAN, Tim, OMARJEE, Saleha, NARANBHAI, Vivek, COOVADIA, Yacoob, NDUNG'U, Thumbi, MOOSA, Mohamed-Yunus S
Format Journal Article
LanguageEnglish
Published Hagerstown, MD Lippincott Williams & Wilkins 24.08.2013
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:HIV-infected patients with treated cryptococcal meningitis are at risk for further neurological deterioration after commencing combination antiretroviral therapy (cART), mostly because of cryptococcosis-associated immune reconstitution inflammatory syndrome (C-IRIS). Identifying predictors of C-IRIS could enable risk stratification. Prospective, longitudinal cohort study for 24 weeks. Durban, South Africa. One hundred and thirty HIV-infected patients with first cryptococcal meningitis episode : Antifungal therapy (amphotericin 1 mg/kg median 14 days, followed by consolidation and maintenance fluconazole) and cART (commenced median of 18 days from cryptococcal meningitis diagnosis). Clinical, blood, and cerebrospinal fluid (CSF) markers associated with C-IRIS before and during cART and clinical significance of CSF cryptococcal culture negativity pre-cART commencement. Of 106 patients commencing cART, 27 (25.5%) developed C-IRIS, 16 (15.1%) neurological deterioration-not C-IRIS, and 63 (59.4%) no neurological deterioration. On multivariable analysis, C-IRIS was associated with persistent CSF cryptococcal growth [hazard ratio (HR) 0.27, P=0.026] and lower CSF protein (HR 0.53, P=0.059) prior to cART and lower CD4 T-cell increases (HR 0.99, P=0.026) but not change in HIV viral load during cART. Using survival analysis, patients with a negative cryptococcal culture pre-cART commencement (n=51; 48.1%) experienced fewer episodes of neurological deterioration, C-IRIS, and cryptococcal relapse/persistence than patients with culture positivity (n=55; 51.9%, HR 0.33, 0.33, and 0.12 and P=0.0003, 0.0042, and 0.0004, respectively). Persistent CSF cryptococcal growth at cART initiation and poor CD4 T-cell increases on cART are strong predictors of C-IRIS. Approaches aimed at achieving CSF culture negativity prior to cART should be evaluated as a strategy to reduce rates of C-IRIS.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0269-9370
1473-5571
DOI:10.1097/qad.0b013e3283614a8d